Aghajanian, Carol

Publications

Sort by

Co-Author Network

selected publications

Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial. Journal for immunotherapy of cancer. 2020 Academic Article GET IT
Times cited: 38
Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Academic Article GET IT
Times cited: 230
Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery. Journal of gynecologic oncology. 2020 Academic Article GET IT
Times cited: 22
Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway. Cancer. 2019 Academic Article GET IT
Times cited: 48
Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer. International journal of cancer. 2019 Academic Article GET IT
Times cited: 37
Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer. Gynecologic oncology. 2019 Academic Article GET IT
Times cited: 39
A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer. Gynecologic oncology. 2019 Academic Article GET IT
Times cited: 9
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. The Lancet. Oncology. 2019 Academic Article GET IT
Times cited: 202
A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study. Gynecologic oncology. 2018 Academic Article GET IT
Times cited: 57
A Phase I Evaluation of Extended Field Radiation Therapy With Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women With Cervical Carcinoma Metastatic to the Para-aortic Lymph Nodes: An NRG Oncology/Gynecologic Oncology Group Study. Gynecologic oncology. 2018 Academic Article GET IT
Times cited: 11
A Randomized Trial of Prophylactic Extended Carboplatin Infusion to Reduce Hypersensitivity Reactions in Recurrent Ovarian Cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2018 Academic Article GET IT
Times cited: 7
A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. Gynecologic oncology. 2018 Academic Article GET IT
Times cited: 117
Adjuvant chemotherapy in patients with operable granulosa cell tumors of the ovary: a surveillance, epidemiology, and end results cohort study. Cancer medicine. 2018 Academic Article GET IT
Times cited: 19
A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors. Investigational new drugs. 2018 Academic Article GET IT
Times cited: 41
Association of ß-hCG Surveillance with Emotional, Reproductive, and Sexual Health in Women Treated for Gestational Trophoblastic Neoplasia. Journal of women's health (2002). 2017 Academic Article GET IT
Times cited: 7
A novel representation of inter-site tumour heterogeneity from pre-treatment computed tomography textures classifies ovarian cancers by clinical outcome. European radiology. 2017 Academic Article GET IT
Times cited: 95
A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852). Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Academic Article GET IT
Times cited: 62
Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Academic Article GET IT
Times cited: 171
Niraparib in Recurrent Ovarian Cancer. The New England journal of medicine. 2017 Article GET IT
Times cited: 6
Tumor Inhibition by Enzalutamide in a Xenograft Model of Ovarian Cancer. Cancer investigation. 2016 Academic Article GET IT
Times cited: 12
Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations. JAMA oncology. 2016 Academic Article GET IT
Times cited: 198
A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study. Gynecologic oncology. 2016 Academic Article GET IT
Times cited: 8
A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D. Gynecologic oncology. 2016 Academic Article GET IT
Times cited: 18
Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Academic Article GET IT
Times cited: 31
A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study). Cancer. 2016 Academic Article GET IT
Times cited: 66
Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 68
Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center. Gynecologic oncology. 2016 Academic Article GET IT
Times cited: 102
Ovarian clear cell carcinoma, outcomes by stage: the MSK experience. Gynecologic oncology. 2015 Academic Article GET IT
Times cited: 66
Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study 0229N. Gynecologic oncology. 2015 Academic Article GET IT
Times cited: 30
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. Gynecologic oncology. 2015 Academic Article GET IT
Times cited: 212
The role of systemic chemotherapy in the management of granulosa cell tumors. Gynecologic oncology. 2014 Academic Article GET IT
Times cited: 44
A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. Gynecologic oncology. 2014 Academic Article GET IT
Times cited: 186
Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2014 Academic Article GET IT
Times cited: 78
Better therapeutic trials in ovarian cancer. Journal of the National Cancer Institute. 2014 Information Resource GET IT
Times cited: 40
Independent radiologic review: bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer. Gynecologic oncology. 2014 Academic Article GET IT
Times cited: 21
Treatment outcomes in completely resected stage I to stage IV uterine carcinosarcoma with rhabdomyosarcoma differentiation. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2013 Academic Article GET IT
Times cited: 2
Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecologic oncology. 2012 Academic Article GET IT
Times cited: 101
Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma. British journal of cancer. 2012 Academic Article GET IT
Times cited: 115
BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. Cancer. 2012 Academic Article GET IT
Times cited: 171
Gemcitabine for advanced endometrial cancer: a retrospective study of the Memorial sloan-Kettering Cancer Center experience. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2012 Academic Article GET IT
Times cited: 10
Genomic complexity and AKT dependence in serous ovarian cancer. Cancer discovery. 2012 Academic Article GET IT
Times cited: 96
Identifying clinical improvement in consolidation single-arm phase 2 trials in patients with ovarian cancer in second or greater clinical remission. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2012 Academic Article GET IT
Times cited: 2
Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer. Cancer. 2011 Academic Article GET IT
Times cited: 77
Immunohistochemical expression of estrogen and progesterone receptors and outcomes in patients with newly diagnosed uterine leiomyosarcoma. Gynecologic oncology. 2011 Academic Article GET IT
Times cited: 54
Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma. Investigational new drugs. 2011 Academic Article GET IT
Times cited: 10
Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Academic Article GET IT
Times cited: 42
Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Academic Article GET IT
Times cited: 274
Treatment of low-risk gestational trophoblastic neoplasia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Editorial Article GET IT
Times cited: 24
Risk factors for recurrence of ovarian borderline tumors. Gynecologic oncology. 2010 Academic Article GET IT
Times cited: 92
Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity. Annals of oncology : official journal of the European Society for Medical Oncology. 2010 Academic Article GET IT
Times cited: 96
Patterns of recurrence and role of adjuvant chemotherapy in stage II-IV serous ovarian borderline tumors. Gynecologic oncology. 2010 Academic Article GET IT
Times cited: 30
Cancer-related infertility in survivorship. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2010 Information Resource GET IT
Times cited: 63
Consolidation strategies in ovarian cancer: observations for future clinical trials. Gynecologic oncology. 2010 Academic Article GET IT
Times cited: 10
Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 Academic Article GET IT
Times cited: 91
Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma. Gynecologic oncology. 2009 Academic Article GET IT
Times cited: 32
The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment. Gynecologic oncology. 2009 Academic Article GET IT
Times cited: 44
Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors. Gynecologic oncology. 2009 Academic Article GET IT
Times cited: 83
A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecologic oncology. 2009 Academic Article GET IT
Times cited: 46
Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecologic oncology. 2009 Academic Article GET IT
Times cited: 418
Incidence of intestinal obstruction following intraperitoneal chemotherapy for ovarian tubal and peritoneal malignancies. Gynecologic oncology. 2009 Academic Article GET IT
Times cited: 16
Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecologic oncology. 2009 Academic Article GET IT
Times cited: 77
Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study. Gynecologic oncology. 2009 Academic Article GET IT
Times cited: 165
Small cell neuroendocrine carcinoma of the cervix: Analysis of outcome, recurrence pattern and the impact of platinum-based combination chemotherapy. Gynecologic oncology. 2008 Academic Article GET IT
Times cited: 108
Concurrent carboplatin/paclitaxel and intravaginal radiation in surgical stage I-II serous endometrial cancer. Gynecologic oncology. 2008 Academic Article GET IT
Times cited: 36
A phase I trial of pemetrexed plus gemcitabine given biweekly with B-vitamin support in solid tumor malignancies or advanced epithelial ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Academic Article GET IT
Times cited: 12
A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma. Gynecologic oncology. 2008 Academic Article GET IT
Times cited: 63
Prognostic factors for patients with stage IV epithelial ovarian cancer receiving intraperitoneal chemotherapy after second-look assessment: results of long-term follow-up. Cancer. 2008 Academic Article GET IT
Times cited: 3
A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer. Gynecologic oncology. 2008 Academic Article GET IT
Times cited: 63
A phase 2 trial of oral imatinib in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma in second or greater remission. European journal of gynaecological oncology. 2008 Academic Article GET IT
Times cited: 16
The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecologic oncology. 2007 Academic Article GET IT
Times cited: 120
Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease 1 cm or less. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 48
Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 115
Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials. Gynecologic oncology. 2007 Academic Article GET IT
Times cited: 30
Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy. Gynecologic oncology. 2007 Academic Article GET IT
Times cited: 58
A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors. Investigational new drugs. 2007 Academic Article GET IT
Times cited: 16
A phase I study evaluating the safety and pharmacokinetics of weekly paclitaxel and carboplatin in relapsed ovarian cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2007 Academic Article GET IT
Times cited: 12
Early CA-125 fluctuations in patients with recurrent ovarian cancer receiving chemotherapy. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2007 Academic Article GET IT
Times cited: 12
Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 88
Squamous cell carcinoma arising in mature cystic teratoma of the ovary: a case series and review of the literature. Gynecologic oncology. 2007 Academic Article GET IT
Times cited: 109
Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2007 Academic Article GET IT
Times cited: 42
Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer. Gynecologic oncology. 2006 Academic Article GET IT
Times cited: 50
Lysophosphatidic acid acyltransferase-beta (LPAAT-beta) is highly expressed in advanced ovarian cancer and is associated with aggressive histology and poor survival. Cancer. 2006 Academic Article GET IT
Times cited: 31
CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy. Gynecologic oncology. 2006 Academic Article GET IT
Times cited: 56
Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Academic Article GET IT
Times cited: 60
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Academic Article GET IT
Times cited: 207
The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecologic oncology. 2006 Academic Article GET IT
Times cited: 269
The role of bevacizumab in ovarian cancer--an evolving story. Gynecologic oncology. 2006 Editorial Article GET IT
Times cited: 27
En bloc resection of diaphragm with lung for recurrent ovarian cancer: a case report. 2006 GET IT
Times cited: 9
The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer Center. Gynecologic oncology. 2006 Academic Article GET IT
Times cited: 264
Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study. Gynecologic oncology. 2006 Academic Article GET IT
Times cited: 51
Phase II study of tirapazamine plus cisplatin in patients with advanced or recurrent cervical cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2006 Academic Article GET IT
Times cited: 30
Surgical resection of recurrent endometrial carcinoma. Gynecologic oncology. 2006 Academic Article GET IT
Times cited: 53
Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioning. Gynecologic oncology. 2006 Academic Article GET IT
Times cited: 26
Topotecan and liposomal doxorubicin in recurrent ovarian cancer: is sequence important?. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2006 Academic Article GET IT
Times cited: 5
New agents for the treatment of ovarian cancer: the next generation. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2005 Information Resource GET IT
Times cited: 11
Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 109
Role of pegylated liposomal doxorubicin in ovarian cancer. Gynecologic oncology. 2005 Information Resource GET IT
Times cited: 96
Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide: a trial of the Gynecologic Oncology Group. Gynecologic oncology. 2004 Academic Article GET IT
Times cited: 45
Clinical update: novel targets in gynecologic malignancies. Seminars in oncology. 2004 Information Resource GET IT
Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 Academic Article GET IT
Times cited: 97
Weekly topotecan for recurrent endometrial cancer: a case series and review of the literature. Gynecologic oncology. 2004 Review GET IT
Times cited: 18
Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma. Cancer. 2004 Academic Article GET IT
Times cited: 108
Phase I and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 Academic Article GET IT
Times cited: 18
The benefit of video-assisted thoracoscopic surgery before planned abdominal exploration in patients with suspected advanced ovarian cancer and moderate to large pleural effusions. Gynecologic oncology. 2004 Academic Article GET IT
Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II Trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Academic Article GET IT
Times cited: 34
Costs of treatment and outcomes associated with second-line therapy and greater for relapsed ovarian cancer. Gynecologic oncology. 2004 Academic Article GET IT
Times cited: 6
Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience. Gynecologic oncology. 2003 Academic Article GET IT
Times cited: 49
Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy. Gynecologic oncology. 2003 Academic Article GET IT
Times cited: 34
Palliative surgery for bowel obstruction in recurrent ovarian cancer:an updated series. Gynecologic oncology. 2003 Academic Article GET IT
Times cited: 77
Craniotomy for central nervous system metastases in epithelial ovarian carcinoma. Gynecologic oncology. 2002 Academic Article GET IT
Times cited: 29
A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002 Academic Article GET IT
Times cited: 394
Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Academic Article GET IT
Times cited: 546
Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Academic Article GET IT
Times cited: 93
Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Academic Article GET IT
Times cited: 109
The costs and efficacy of liposomal doxorubicin in platinum-refractory ovarian cancer in heavily pretreated patients. Gynecologic oncology. 2001 Academic Article GET IT
Times cited: 20
Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look. Gynecologic oncology. 2000 Academic Article GET IT
Times cited: 6
Immunization of ovarian cancer patients with a synthetic Lewis(y)-protein conjugate vaccine: a phase 1 trial. International journal of cancer. 2000 Academic Article GET IT
Times cited: 117
Phase II trial of intraperitoneal cisplatin and mitoxantrone in patients with persistent ovarian cancer. Gynecologic oncology. 1999 Academic Article GET IT
Times cited: 21
Chemotherapy in gynecologic cancer. Current opinion in oncology. 1998 Information Resource GET IT
Times cited: 4
Phase II study of "dose-dense" high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998 Academic Article GET IT
A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with Stage II-IV epithelial ovarian cancer following negative surgical assessment. Gynecologic oncology. 1998 Academic Article GET IT
Times cited: 80
Management of malignant germ cell tumors of the ovary. Seminars in oncology. 1998 Information Resource GET IT
Times cited: 36
Posttranscriptional regulation of protein expression in human epithelial carcinoma cells by adenine-uridine-rich elements in the 3'-untranslated region of tumor necrosis factor-alpha messenger RNA. Cancer research. 1997 Academic Article GET IT
Times cited: 43
Phase I study of tirapazamine and cisplatin in patients with recurrent cervical cancer. Gynecologic oncology. 1997 Academic Article GET IT
Times cited: 23
UCN-01 in ovary cancer cells: effective as a single agent and in combination with cis-diamminedichloroplatinum(II)independent of p53 status. Clinical cancer research : an official journal of the American Association for Cancer Research. 1997 Academic Article GET IT
Times cited: 58
Metastatic breast carcinoma to the abdomen and pelvis. Gynecologic oncology. 1997 Academic Article GET IT
Times cited: 33
Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997 Academic Article GET IT
The impact of diabetes mellitus on the toxicity of therapy for advanced ovarian cancer. Gynecologic oncology. 1996 Academic Article GET IT
Times cited: 52

more ...

less ...

Background

education and training

M.D., State University of New York Health Science Center at Brooklyn 1989
B.A., Boston University 1985

Contact

full name

Carol Aghajanian

VIVO Weill Cornell Medical College

Carol Aghajanian Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name